Subscribe to Grünenthal Group
  • 14.07.2022 – 08:02

    Grünenthal acquires testosterone treatment NebidoTM from Bayer

    Aachen, Germany (ots) - - Grünenthal acquires NebidoTM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal’s EBITDA in 2023. - NebidoTM is the gold standard for the treatment ofmale hypogonadism associated with testosterone deficiency. It is available to patients in over 80 markets worldwide. - Grünenthal has invested over € 2 billion in successful M&A ...

  • 07.03.2022 – 12:15

    Grünenthal donates 400.000EUR and provides pain treatment medicine to Ukraine

    Aachen (ots) - Grünenthal, an international science-driven pharmaceutical company, announced that it has donated 400.000EUR to the Red Cross to support humanitarian relief efforts in Ukraine and Eastern Europe. In addition, Grünenthal partners with Action Medeor and the University Hospital of RWTH Aachen to provide urgently needed pain medication to the region. The ...

  • 24.01.2022 – 09:37

    EFIC® and Grünenthal Announced Winners of Pain Research Grant 2022

    Brussels/Aachen (ots) - - Five promising early-career scientists have been awarded the prestigious EFIC-Grünenthal Grant (E-G-G) 2022 - The E-G-G funds innovative research projects to advance understanding of pain, and improve the lives of people with pain The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have announced the five recipients ...

  • 10.08.2021 – 09:00

    First patient enrolled into a Phase III study with QUTENZA® in post-surgical neuropathic pain

    Aachen, Germany and Morristown, N.J. (ots) - - The study AV001 aims to include the treatment of post-surgical neuropathic pain (PSNP) in the U.S. label. QUTENZA® is currently approved for use in adults in the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy ...

  • 27.07.2021 – 10:15

    Grünenthal’s Glucocorticoid Receptor Modulator enters clinical development

    Aachen (ots) - Grünenthal announced today that the first volunteers have been enrolled in a Phase I trial of its Glucocorticoid Receptor Modulator (GRM). The oral investigational medicine aims to provide a therapy option with broad anti-inflammatory efficacy and a more favourable benefit-risk profile compared to current glucocorticoid-based therapies like ...